Late Breaking Original Research
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Introduction: The misuse of antimicrobials within children is fueled by a lack of pediatric-specific data. Ceftaroline fosamil (CPT) is a novel cephalosporin FDA-approved in children for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. Despite the accumulating evidence in adults, there is a substantial void of real-world data to guide CPT use in the pediatric population.
Research Question or Hypothesis: What are the real-world clinical outcomes in the pediatric population following treatment with CPT?
Study Design: Retrospective, observational cohort.
Methods: Any pediatric inpatients treated with CPT between July 2014 to June 2023 were included. Baseline demographics, as well as clinical/microbiologic data, were extracted from electronic medical records. The primary outcome was clinical success in patients that received =48 hours of therapy: defined as a composite of survival at 30 days, lack of 30-day microbiologic recurrence, and resolution in signs/symptoms of acute infection, without therapy modification based on clinical failure. Secondary outcomes included adverse effects and provider motives for utilization. Descriptive statistics were utilized for analysis.
Results: Overall, 20 patients were included: median (IQR) age and weight were 3.5 (2.0-10.7) years and 16.2 (11.8-35.1) kg, respectively; 50.0% were Caucasian, 65.0% were male, and the majority (65.0%) received intensive unit care. The pediatric infectious diseases service was involved in all cases. The most frequently isolated pathogens included Staphylococcus aureus (50.0%), coagulase negative staphylococci (12.5%), and Streptococcus pneumoniae (12.5%). The most common dosage regimen and infectious site was CPT 12 mg/kg IV q8h (50.0%) and was of respiratory origin (45.0%), respectively. Clinical success occurred in 92.3% of cases, while no patients experienced an adverse effect while on therapy. Common motives for CPT use included regimen consolidation or synergistic effects.
Conclusion: CPT represents a promising option for use in children given the degree of clinical success and no observed adverse effects. Larger, multicenter studies are needed to validate our preliminary findings.
Presenting Author
Taylor Morrisette Pharm.D., M.P.H.Medical University of South Carolina College of Pharmacy
Authors
Gustavo Alvira-Arill PharmD
Medical University of South Carolina College of Pharmacy
Krutika Mediwala Hornback PharmD, BCPS, BCIDP
Medical University of South Carolina
Amy Miller PharmD Candidate
University of South Carolina College of Pharmacy
Stephen Thacker MD
Medical University of South Carolina Health